ToolGen Inc. and Thermo Fisher Scientific Inc. have signed an agreement under which ToolGen will license its CRISPR/Cas9 intellectual property portfolio to Thermo Fisher Scientific. Thermo Fisher will utilize the technology to develop and market new CRISPR reagent kits, bringing new tools to researchers. The kits will augment Thermo Fisher's strong portfolio in the complementary transcription activator-like effector nucleases (TALEN) technique.

Under the terms of the agreement, Thermo Fisher Scientific is granted a worldwide license for research applications including the development and sale of reagents, cell lines, and animal models, as well as rights for high throughput screening, diagnostics, and bio production. Thermo Fisher Scientific also has the right to grant sublicenses in each of these fields.